Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02043288
Previous Study | Return to List | Next Study

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02043288
Recruitment Status : Completed
First Posted : January 23, 2014
Last Update Posted : April 15, 2020
Sponsor:
Collaborator:
NanoCarrier Co., Ltd.
Information provided by (Responsible Party):
Orient Europharma Co., Ltd.

Brief Summary:
This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.

Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Drug: NC-6004 Drug: Gemcitabine Phase 3

Detailed Description:

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. NC-6004, a novel micellar cisplatin formulation, retains the activity but avoids the renal toxicity and neurotoxicity caused by the high peak Cmax concentrations of cisplatin. This trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer.

The main hypothesis of this study is that NC-6004 plus gemcitabine combination is superior to gemcitabine alone in terms of overall survival in locally advanced or metastatic pancreatic cancer patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 310 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Actual Study Start Date : January 2014
Actual Primary Completion Date : December 2019
Actual Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NC-6004 and Gemcitabine combination
NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
Drug: NC-6004

Study group (3 week/cycle):

NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1

Other Name: Micelplatin

Drug: Gemcitabine

Study group (3 week/cycle):

Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)

Control group (4 week/cycle):

Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15

Other Name: Gemzar

Active Comparator: Gemcitabine monotherapy
Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
Drug: Gemcitabine

Study group (3 week/cycle):

Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)

Control group (4 week/cycle):

Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15

Other Name: Gemzar




Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 3.5 years ]
    Overall survival is defined as the time from the treatment initiation until death from any cause, and censored at the last follow up time.


Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 3.5 years ]
    Progression free survival is defined as the time from the treatment initiation until progression or death, and censored at the last follow up time.

  2. Response rate (RR) and disease control rate (DCR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria [ Time Frame: 3.5 years ]
    • Response rate is defined as counts and proportions of patients responding complete response or partial response within the duration of the study.
    • Disease control rate is defined as counts and proportions of patients responding complete response, partial response or progressive disease within the duration of the study.

  3. Duration of response [ Time Frame: 3.5 years ]
    • Duration of overall response (DOR) will be measured from the time of initial response (CR or PR) until documented progression or death, and censored at last follow up time.
    • Duration of stable disease (DSD) will be measured from the time of initial stable disease (SD) until documented progression or death, and censored at last follow up time.

  4. CA19-9 [ Time Frame: 3.5 years ]
    CA19-9 values and changes from baseline will be summarized.

  5. Quality of life (QoL) using EORTC QLQ-C30 [ Time Frame: 3.5 years ]
    Quality of life (QoL) values and changes from baseline will be summarized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Male or female aged between 20 to 80 years (inclusive)
  2. Unresectable, histologically or cytologically confirmed, locally advanced or metastatic pancreatic cancer (adenocarcinoma, adenosquamous carcinoma or poorly differentiated carcinoma)
  3. Presence of at least one measurable tumor lesion (longest diameter ≥ 10 mm)
  4. No prior systemic anti-cancer therapy* and radiotherapy** for advanced pancreatic cancer

    * Patients with post-operative adjuvant chemotherapy other than platinum products (e.g. cisplatin, carboplatin and oxaliplatin, etc.) or radiotherapy or chemo-radiotherapy completed more than 6 months before recurrence will be eligible.

    ** Patients with prior palliative radiotherapy of < 20% bone marrow involvement prior to 6 months from screening will be eligible.

  5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
  6. Adequate organ function defined as:

    • 3,000 cells/μL ≤ WBC ≤ 12,000 cells/μL
    • Absolute neutrophils count (ANC) ≥ 1,500 cells/μL
    • Platelets ≥ 100,000 cells/μL
    • Hemoglobin (Hb) ≥ 9.0 g/dL
    • Alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤ 2.5 times the upper limit of normal (ULN) in patients with no demonstrable hepatic metastasis, or ≤ 5 x ULN in patients with hepatic metastasis
    • Serum bilirubin ≤ 1.5 x ULN in patients with no demonstrable hepatic metastasis and obstructive jaundice, or ≤ 2.5 x ULN in patients with hepatic metastasis or obstructive jaundice
    • Serum creatinine (SCr) ≤ 1.5 mg/dL and creatinine clearance (CrCl) ≥ 60 mL/min (from 24-hour urine test or Cockcroft-Gault formula)
    • Corrected serum calcium ≤ ULN
  7. If fertile*, willing to use barrier contraception till 6 months after the end of treatment

    * With the following exceptions: 1) pre-menopausal females with bilateral tubal ligation, bilateral oophorectomy or hysterectomy; 2) post-menopausal women, defined as 12 months of spontaneous amenorrhea; 3) males with vasectomy.

  8. Willing and able to comply with study procedures and provide written informed consent

Exclusion criteria:

  1. Pregnancy or breastfeeding
  2. Active concomitant malignancy or history of other cancer except carcinoma in situ of cervical squamous cell carcinoma, stage I colon cancer or other malignance that has remained disease-free for more than 3 years after curative intervention
  3. Metastasis to the central nervous system or brain
  4. Evidence of hearing impaired ≥ Grade 2 as assessed by pure tone audiometry or other neurotoxicity ≥ Grade 2

    * Patients with age-associated hearing loss at the high frequencies that, in the judgment of the investigator, would not interfere significantly with patient's safety or study assessments will be eligible to enroll.

  5. Patient with pulmonary fibrosis or interstitial pneumonia
  6. Marked pleural effusion or ascites above Grade 2
  7. Patient with known HIV infection
  8. Patient with active hepatitis B, hepatitis C or any other ongoing severe infections
  9. Patient with severe mental disorder
  10. As judged by the investigator, any evidence of significant laboratory findings or severe/uncontrolled clinical disorders (e.g. dementia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, active cardiomyopathy, unstable arrhythmia, and other unstable or uncompensated respiratory, cardiac, hepatic, renal and/or infectious disease)
  11. Patient with known hypersensitivity to Pt compounds
  12. Known severe drug hypersensitivity
  13. Treatment with a non-approved or investigational product within 30 days before Day 1 of study treatment
  14. Alcoholic liver disease* or liver disease with obvious clinical symptom or sign

    * the investigator should judge from medical examination by interview and laboratory test including γ-GTP, AST and ALT

  15. Daily Alcohol consumption within 6 months before the screening as an average weekly intake of >21 units (168 g of pure alcohol) or an average daily intake of >3 units (24 g of pure alcohol) for males / an average weekly intake of >14 units (112 g of pure alcohol) or an average daily intake of >2 units (16 g of pure alcohol) for females.

    Kind of Alcohol Alcohol Percentage mL per 1 unit =8 g of pure alcohol

    Beer 5 % 200 mL

    Whiskey/Brandy 40 % 25 mL

    Wine 12 % approx. 83 mL

    Sake 15 % approx. 67 mL

    Distilled spirit 25 % 40 mL

    Kaoliang 50 % 20 mL

  16. Patient with uncontrolled diabetes
  17. Radiotherapy within 6 months before screening
  18. Experienced Abdominal Radiotherapy
  19. Experienced treatment of Gemtuzumab ozogamicin
  20. Patient with autoimmune hepatitis or idiopathic thrombocytopenic purpura (ITP)
  21. Observation of "attenuated or reversed hepatic venous portal blood flow*" was confirmed by doppler ultrasonography or CT (recommend evaluation in arterial phase, portal-venous phase and equilibrium phase) of the liver * On doppler ultrasonography of right and left branch of portal vein, blood flow is measured as about 0 mL/min or between plus and minus, which indicate obvious blood flow obstruction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02043288


Locations
Show Show 43 study locations
Sponsors and Collaborators
Orient Europharma Co., Ltd.
NanoCarrier Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Li-Tzong Chen, M.D., Ph. D. National Institute of Cancer Research, National Health Research Institutes
Layout table for additonal information
Responsible Party: Orient Europharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT02043288    
Other Study ID Numbers: NC-6004-005
First Posted: January 23, 2014    Key Record Dates
Last Update Posted: April 15, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Orient Europharma Co., Ltd.:
Pancreatic cancer
Platinum
Micelle
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs